IMMUNE CHECKPOINT INHIBITORS
Late Cardiac Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors
Compared with patients who experienced cardiac adverse events (CAEs) related to immune checkpoint inhibitor (ICI) therapy 90 days or less after treatment initiation, those with late ICI-associated CAEs (ie, more than 90 days after treatment initiation) experienced significantly more left ventricular systolic dysfunction and heart failure and less frequent supraventricular arrhythmias.
Journal for ImmunoTherapy of CancerMeet the Faculty
Videos
-
Immune Checkpoint Inhibitors Managing Cardiotoxicity Associated With Immune Checkpoint Inhibitor Therapy
-
Immune Checkpoint Inhibitors Immune Checkpoint Inhibitors and Cardiotoxicity: Incidence and Patient Risk Factors
-
Immune Checkpoint Inhibitors Immune Checkpoint Inhibitors and Cardiotoxicity: The Pharmacist Perspective
